title: Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
abstract: OBJECTIVE
  To investigate the efficacy and safety of the combination therapy of irinotecan (CPT-11) plus S-1 in patients with advanced gastric cancer at the dose recommended by a previous phase I study.
  
  
  METHODS
  A total of 23 patients received 80 mg/m(2) of CPT-11 on days 1 and 15, and S-1 at a dose level set on the basis of the body surface area (BSA): 40 (BSA <1.25 m(2)), 50 (BSA > or =1.25 to <1.5 m(2)) or 60 mg (BSA > or =1.5 m(2)) b.i.d. was given from days 1-21.
  
  
  RESULTS
  The overall response rate was 47.8% (11 of 23, 95% confidence interval, CI: 27.4-68.2%). The median time to progression (TTP) was 210 days (95% CI: 145-322 days) and the median survival time was 394 days (95% CI: 241-484 days). The incidence of grade 3 or 4 hematological and non-hematological toxicity was 17.4 and 8.7%. The most common hematological toxicity was anemia and the most common non-hematological toxicity was diarrhea.
  
  
  CONCLUSIONS
  The combination therapy of CPT-11 and S-1 provided prolonged TTP with low toxicity, and the results warrant a further phase III study to define the efficacy in improvement of survival in patients with advanced gastric cancer.
authors.affiliation: Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.uedou-no@mc.pref.osaka.jp
authors.forename: Noriya
authors.initials: N
authors.lastname: Uedo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Narahara
authors.forename: Ryu
authors.initials: R
authors.lastname: Ishihara
authors.forename: Hiroya
authors.initials: H
authors.lastname: Takiuchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Goto
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hirao
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: Motohiro
authors.initials: M
authors.lastname: Imano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tsukuma
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Taguchi
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin